Protagen specializes in pharma co-development services to provide effective tools that support the development of novel treatments for autoimmune diseases. Using its proprietary biomarker screening platform, SeroTag®, Protagen has developed an array of disease-specific stratification panels, the NavigAID tools, to accurately profile individual patients’ diseases, and stratify patients into distinct disease subgroups that help predict treatment response and inform clinical decisions. In this way, Protagen is tackling topical challenges in autoimmune disease therapeutics, and helping to improve treatment efficacy.
Protagen’s NavigAID stratification tools can separate patients with a range of autoimmune conditions, to improve response prediction and assess the specific immunological processes underpinning the disease to better inform treatments.
Protagen’s Multilisa® assays can also help in the detection of disease-associated antigens, to help diagnose autoimmune diseases such as Systemic Sclerosis (SSc) and Systemic Lupus Erythematosus (SLE) at an early stage and profile disease mechanisms in individual patients. By implementing these tools, Protagen can support drug development by:
- Improving the characterization of different autoimmune diseases
- Enhancing treatment response prediction via patient stratification and monitoring